<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04998981</url>
  </required_header>
  <id_info>
    <org_study_id>K-877-3.01CH</org_study_id>
    <nct_id>NCT04998981</nct_id>
  </id_info>
  <brief_title>A Phase 3 Study to Evaluate the Efficacy and Safety of K-877 in Chinese Patients With High TG and Low HDL-C</brief_title>
  <official_title>A Phase 3, Multi-Center, Placebo- and Active-Controlled, Randomized, Double-Blind, 12-Week Study to Evaluate the Efficacy and Safety of K-877 in Chinese Patients With High TG and Low HDL-C</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Kowa Company, Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Kowa Company, Ltd.</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      A Phase 3 Study to Evaluate the Efficacy and Safety of K-877 in Chinese Patients with High TG&#xD;
      and Low HDL-C&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">September 17, 2021</start_date>
  <completion_date type="Anticipated">February 2, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 2, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Percent change in fasting TG versus placebo from baseline to Weeks 8 and 12</measure>
    <time_frame>From baseline to Weeks 8 and 12</time_frame>
  </primary_outcome>
  <primary_outcome>
    <measure>Percent change in fasting TG versus fenofibrate from baseline to Weeks 8 and 12</measure>
    <time_frame>From baseline to Weeks 8 and 12</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Percentage of patients who have achieved fasting TG &lt;150 mg/dL at the end of the treatment period</measure>
    <time_frame>At Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline to Weeks 8 and 12 in TC, LDL-C (direct method), LDL-C (Friedewald method), LDL-C (Martin/Hopkins equation), HDL-C (direct method), non-HDL-C (calculated), and remnant cholesterol (calculated)</measure>
    <time_frame>From baseline to Weeks 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Weeks 8 and 12 in fasting TG, TC, LDL-C (direct method), LDL-C (Friedewald method), LDL-C (Martin/Hopkins equation), HDL-C (direct method), non-HDL-C (calculated), and remnant cholesterol (calculated)</measure>
    <time_frame>From baseline to Weeks 8 and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline to the end of the treatment period in Apo A1 and Apo B</measure>
    <time_frame>From baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Percent change from baseline to the end of the treatment period in TG/HDL-C, TC/HDL-C, non-HDL-C/HDL-C, LDL-C/HDL-C, LDL-C/Apo B, and Apo B/Apo A1</measure>
    <time_frame>From baseline to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The incidence of adverse events and adverse drug reactions after the administration of the study drug</measure>
    <time_frame>Up to Week 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change from baseline to Week 4, 8, and 12 in clinical laboratory tests (chemistry, hematology), vital signs (BP [mmHg], PR [bpm], weight [kg], waist [cm], and BMI [kg/m^2]; each parameter is evaluated individually.), 12-lead ECGs</measure>
    <time_frame>From baseline to Week 4, 8, and 12</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number and percentage of patients who experience laboratory abnormalities of special interest including, but not limited to ALT, AST, ALP, CK, and, creatinine during the treatment period</measure>
    <time_frame>Up to Week 12</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">350</enrollment>
  <condition>Hyperlipidemia</condition>
  <arm_group>
    <arm_group_label>K-877 0.1 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>K-877 0.1 mg tablet twice daily, Placebo tablet twice daily, Placebo capsule once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>K-877 0.2 mg BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>K-877 0.1 mg tablet x 2 twice daily, Placebo capsule once daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fenofibrate 200 mg QD</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fenofibrate 200 mg capsule once daily, Placebo tablet x 2 twice daily</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placcebo tablet x 2 twice daily, Placebo capsule once daily</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>K-877 0.1 mg tablet</intervention_name>
    <description>K-877 0.1 mg tablet x 2 twice daily</description>
    <arm_group_label>K-877 0.2 mg BID</arm_group_label>
    <other_name>Pemafibrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fenofibrate 200 mg capsule</intervention_name>
    <description>Fenofibrate 200 mg capsule once daily</description>
    <arm_group_label>Fenofibrate 200 mg QD</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablet</intervention_name>
    <description>Placebo tablet x 2 twice daily</description>
    <arm_group_label>Fenofibrate 200 mg QD</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo tablet (matching K-877)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo capsule</intervention_name>
    <description>Placebo capsule once daily</description>
    <arm_group_label>K-877 0.1 mg BID</arm_group_label>
    <arm_group_label>K-877 0.2 mg BID</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
    <other_name>Placebo capsule (matching fenofibrate)</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>K-877 0.1 mg tablet</intervention_name>
    <description>K-877 0.1 mg tablet twice daily</description>
    <arm_group_label>K-877 0.1 mg BID</arm_group_label>
    <other_name>Pemafibrate</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo tablet</intervention_name>
    <description>Placebo tablet twice daily</description>
    <arm_group_label>K-877 0.1 mg BID</arm_group_label>
    <other_name>Placebo tablet (matching K-877)</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        Subjects are eligible to be included in the study only if all of the following criteria&#xD;
        apply:&#xD;
&#xD;
          1. Ability to understand and comply with study procedures and give written informed&#xD;
             consent&#xD;
&#xD;
          2. Following the diet and lifestyle recommendations at least 12 weeks prior to the&#xD;
             treatment period&#xD;
&#xD;
          3. Males or post-menopausal females&#xD;
&#xD;
          4. Aged ≥18 years at the time of informed consent&#xD;
&#xD;
          5. Fasting serum TG levels ≥200 mg/dL (≥2.26 mmol/L) and ≤500 mg/dL (5.65 mmol/L) at&#xD;
             screening&#xD;
&#xD;
          6. Serum HDL-C &lt;50 mg/dL (&lt;1.30 mmol/L) if male or &lt;55 mg/dL (&lt;1.42 mmol/L) if female at&#xD;
             screening.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        Subjects are excluded from the study if any of the following criteria apply:&#xD;
&#xD;
          1. Current or planned use of any lipid-altering medications other than the study drugs,&#xD;
             statins, or ezetimibe during the study.&#xD;
&#xD;
             i. Subjects currently on statins or ezetimibe must be at high risk for atherosclerotic&#xD;
             CV diseases, and the dose(s) must be stable for at least 4 weeks prior to screening&#xD;
&#xD;
             ii. For subjects currently on lipid-altering medications other than statins or&#xD;
             ezetimibe, at least 4-week washout period (or for subjects currently on probucol at&#xD;
             least 8 week washout period) will be required prior to the first fasting blood&#xD;
             sampling at Screening Visit&#xD;
&#xD;
          2. Type 1 diabetes mellitus or poorly controlled Type 2 diabetes mellitus defined by&#xD;
             HbA1c (NGSP level) ≥8.0% at screening&#xD;
&#xD;
          3. Uncontrolled hypertension defined by seated systolic blood pressure ≥160 mmHg and/or&#xD;
             diastolic blood pressure ≥100 mmHg at screening&#xD;
&#xD;
          4. Uncontrolled thyroid disorder&#xD;
&#xD;
          5. Creatinine ≥1.5 mg/dL at screening&#xD;
&#xD;
          6. Severe hepatic disorder defined as cirrhosis of Child-Pugh class B or C, or AST or ALT&#xD;
             &gt;2 × ULN at screening&#xD;
&#xD;
          7. History of pancreatitis&#xD;
&#xD;
          8. Gallbladder disorder, history of cholelithiasis, primary biliary cirrhosis, or history&#xD;
             of disease or surgery that may affect the absorption, distribution, metabolism and&#xD;
             excretion of drugs or the metabolism of bile salts&#xD;
&#xD;
          9. Unexplained creatine kinase (CK) &gt;5 × ULN at screening&#xD;
&#xD;
         10. Myocardial infraction or stroke (including transient ischemic attack) within 3 months&#xD;
             prior to the informed consent&#xD;
&#xD;
         11. New York Heart Association Class III or IV heart failure&#xD;
&#xD;
         12. History of malignancy within 5 years&#xD;
&#xD;
         13. Participation in another clinical study at the time of informed consent or&#xD;
             administration of an investigational drug other than placebo within 16 weeks prior to&#xD;
             the informed consent for this study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Keisuke Kunitomi</last_name>
    <phone>81-3-3279-7454</phone>
    <email>ctrdinfo@kowa.co.jp</email>
  </overall_contact>
  <location>
    <facility>
      <name>Huainan First People's Hospital</name>
      <address>
        <city>Anhui</city>
        <zip>232000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beijing Anzhen Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <zip>100029</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beijing Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beijing Tongren Hospital, Capital Medical University</name>
      <address>
        <city>Beijing</city>
        <zip>100730</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Beijing Pinggu Hospital</name>
      <address>
        <city>Beijing</city>
        <zip>101200</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Chengdu Xinhua Hospital</name>
      <address>
        <city>Chengdu</city>
        <zip>610066</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Fujian Medical University</name>
      <address>
        <city>Fujian</city>
        <zip>350005</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital, Sun Yat-sen University</name>
      <address>
        <city>Guangdong</city>
        <zip>510080</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The People's Hospital of Guangxi Zhuang Autonomous Region</name>
      <address>
        <city>Guangxi</city>
        <zip>530021</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Second Hospital of Hebei Medical University</name>
      <address>
        <city>Hebei</city>
        <zip>050000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Harbin Medical University</name>
      <address>
        <city>Helongjiang</city>
        <zip>150001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Union Hospital, Tongji Medical College of Huazhong University of Science &amp; Technology</name>
      <address>
        <city>Hubei</city>
        <zip>430022</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tongji Hospital, Tongji Medical College of HUST</name>
      <address>
        <city>Hubei</city>
        <zip>430030</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shaanxi Provincial People's Hospital</name>
      <address>
        <city>Hubei</city>
        <zip>710068</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>The Third Hospital of Changsha</name>
      <address>
        <city>Hunan</city>
        <zip>410015</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
  </location>
  <location>
    <facility>
      <name>Sir Run Run Hospital Nanjing Medical Universtiy</name>
      <address>
        <city>Jiangsu</city>
        <zip>211100</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Affiliated Hospital of Jiangsu University</name>
      <address>
        <city>Jiangsu</city>
        <zip>212001</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>The First Affiliated Hospital of Nanchang University</name>
      <address>
        <city>Jiangxi</city>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Jiu Jiang No. 1 People's Hospital</name>
      <address>
        <city>Jiangxi</city>
        <zip>332000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Pingxiang People's Hospital</name>
      <address>
        <city>Jiangxi</city>
        <zip>337055</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>China-Japan Union Hospital of Jilin University</name>
      <address>
        <city>Jilin</city>
        <zip>330006</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Shanghai Tongren Hospital</name>
      <address>
        <city>Shanghai</city>
        <zip>200336</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Tianjin Union Medical Center</name>
      <address>
        <city>Tianjin</city>
        <zip>300121</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>People's Hospital of Wenzhou City</name>
      <address>
        <city>Zhejiang</city>
        <zip>325000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>September 2021</verification_date>
  <study_first_submitted>July 14, 2021</study_first_submitted>
  <study_first_submitted_qc>August 3, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">August 10, 2021</study_first_posted>
  <last_update_submitted>September 26, 2021</last_update_submitted>
  <last_update_submitted_qc>September 26, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 1, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipidemias</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Fenofibrate</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

